Regenerative Medical Technology Group stock analysis
Want to see RMTG full AI Analyst Report?
Regenerative Medical Technology Group (RMTG) Stock Price & Analysis
RMTG Stock Chart & Stats
- Day’s Range
- $0.03 - $0.03
- 52-Week Range
- $0.02 - $0.13
- Previous Close
- $0.03
- Volume
- N/A
- Average Volume (3M)
- 40.39K
- Market Cap
- $412.17K
- Enterprise Value
- $21.03M
- Total Cash (Recent Filing)
- $1.32M
- Total Debt (Recent Filing)
- $21.74M
- Price to Earnings (P/E)
- ―
- Beta
- -1.53
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth
Rapid revenue expansion demonstrates meaningful demand for the company’s regenerative medicine offerings and provides a larger base over which fixed costs can be absorbed. If sustained, this momentum could improve operating leverage and support broader market development.
Solid Gross Economics
A gross margin near 60% indicates that the products and services generate useful contribution after direct costs. The move to slightly positive EBIT also suggests improving operating discipline, although continued scale and cost control are needed to convert this into durable profitability.
Scalable Commercial Platform
The combination of education, product sales, clinical activity, and physician training creates multiple routes to customer acquisition and recurring demand. Management’s focus on higher-margin products, affiliate revenue, and network expansion could strengthen the business model as adoption grows.
Bears Say
Stressed Balance Sheet
Negative equity and debt that is large relative to assets leave the company with little financial cushion for creditors or shareholders. This stressed capital structure can constrain investment, increase dependence on financing, and make balance-sheet repair a multi-quarter priority.
Persistent Net Losses
The company’s gross profit and improved EBIT have not yet translated into bottom-line earnings, with losses still exceeding revenue by a substantial amount. Continued net losses can consume capital, delay self-funding, and weaken the ability to finance expansion without outside support.
Negative Free Cash Flow
Negative free cash flow means current operations are not yet funding capital spending and growth requirements. Even with a modest improvement in operating cash flow, ongoing cash burn may require continued external financing and limits flexibility to address liabilities or invest selectively.
Regenerative Medical Technology Group News
RMTG FAQ
What was Regenerative Medical Technology Group’s price range in the past 12 months?
What is Regenerative Medical Technology Group’s market cap?
When is Regenerative Medical Technology Group’s upcoming earnings report date?
How were Regenerative Medical Technology Group’s earnings last quarter?
Is Regenerative Medical Technology Group overvalued?
Does Regenerative Medical Technology Group pay dividends?
What is Regenerative Medical Technology Group’s EPS estimate?
How many shares outstanding does Regenerative Medical Technology Group have?
What happened to Regenerative Medical Technology Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Regenerative Medical Technology Group?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Regenerative Medical Technology Group
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of stem cell therapies. The company is also involved in the treatment of patients; provision of training and seminars; and resale of kits, products, equipment, and services. In addition, it offers reoccurring application of its process using its kits and solutions. The company was formerly known as Meso Numismatics, Inc. and changed its name to Regenerative Medical Technology Group Inc. in May 2024. Regenerative Medical Technology Group Inc. was incorporated in 1999 and is based in Boca Raton, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Christensen
- Employees
- 1
- Website
- regenmedtechgroup.com
- Address
- 433 Plaza Real, Boca Raton, FL, 33432, US
Regenerative Medical Technology Group (RMTG) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 4 | 13 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 2 | 0 | 10 |








